This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Quality of Life  • Immunology, Other  • Neurology  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The clinical review by Dr Dalakas¹ underscores that intravenous immunoglobulin (IVIG) is the treatment of choice in Guillain-Barré syndrome (GBS), multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy (CIDP) and that it is useful instead of plasma exchange for management of myasthenia gravis. On the other hand, he stresses the necessity of further studies of dose-finding effects, pharmacoeconomics, and quality of life (QOL) assessments to improve the evidence base for clinical practice.

We believe that our research is a step in this direction. We prospectively followed up 25 patients treated with IVIG to evaluate the early effects on their health-related QOL.² The patients (15 male, 10 female; mean age, 51.3 [SD, 16.8] years; range, 17-77), were admitted to our Neurology department: 8 with CIDP, 3 with GBS, 3 with multifocal motor neuropathy, 1 with multineuropathy of cranial nerves, and 10 with myasthenia gravis. All were treated with . . . [Full Text of this Article]

Luca Padua, MD, PhD
lpadua@rm.unicatt.it
Fondazione Pro Iuventute
Istituto Don C. Gnocchi
Rome, Italy

Irene Aprile, MD; Pietro Caliandro, MD; Costanza Pazzaglia, MD; Pietro Tonali, MD
Institute of Neurology
Università Cattolica
Rome

RELATED ARTICLE

Intravenous Immunoglobulin and Quality of Life—Reply
Marinos C. Dalakas
JAMA. 2004;292(12):1429-1430.
EXTRACT | FULL TEXT